Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Første gang i menneskelig studie av langtidsvirkende VH4524184-formuleringer

2. november 2026 oppdatert av: ViiV Healthcare

En fase 1 dobbeltblind (sponsor-ublindet), placebokontrollert randomisert, enkelt stigende dose og multiple dose studie for å undersøke sikkerheten, tolerabiliteten og farmakokinetikken til parenteralt administrert VH4524184 hos friske voksne

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

348

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Kansas
      • Lenexa, Kansas, Forente stater, 66219
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Patrick Yao
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89113
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aishwarya Vyas-Lahar
    • Texas
      • Austin, Texas, Forente stater, 78744
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sean Gilbey
      • San Antonio, Texas, Forente stater, 78232
        • Rekruttering
        • GSK Investigational Site
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Robert Bass
    • Utah
      • Salt Lake City, Utah, Forente stater, 84124
        • Rekruttering
        • GSK Investigational Site
        • Hovedetterforsker:
          • Ahad Sabet
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Age

-Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.

Type of Participant and Characteristics

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.

Weight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive) for all cohorts except B19. For Cohort B19, body mass index within the range >32.0 to 37.0 kg/m^2 (inclusive).

Sex and Contraceptive/Barrier Requirements

  • Male or female

    1. Male Participants: No restrictions for male participants

    2. Participants of female sex assigned at birth:

      • A participant of childbearing potential (POCBP) (female sex assigned at birth) is eligible to participate as long as the participant is not pregnant, breastfeeding and utilizes a highly effective method of contraception.
      • A participant of non-childbearing potential (PONCBP) is eligible to participate if all other eligibility criteria are met.

      Informed Consent

  • Capable of providing signed informed consent.

Exclusion Criteria:

Medical Conditions

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Clinically significant abnormal blood pressure as determined by the investigator.
  • Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  • Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome.
  • Underlying skin disease or disorder that would interfere with the administration of study product and/or assessment of injection site reactions.
  • Clinically significant history of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reactions, as well as history of /sensitivity to any of the study interventions including hyaluronidases.
  • Current or anticipated need for chronic anti-coagulation except for the use of low dose acetylsalicylic acid (≤325 mg) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
  • History of seizure.
  • Any known or suspected pre-existing psychiatric condition, including depression, anxiety and insomnia/sleep disturbances, at the discretion of the investigator.
  • Any positive (abnormal) response confirmed by the investigator or clinician (or qualified designee) administered C-SSRS at screening.
  • Insufficient muscle mass (gluteus medius or thigh) to support IM dose administration in the opinion of the investigator.
  • Presence of tattoos, implants or skin piercings that may interfere with the administration of study product and/or assessment of ISRs, if they occur.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator. This includes participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.

Prior/Concomitant Therapy

  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Receipt of any live vaccine(s) within 28 days prior to screening or 14 days before or after scheduled SC or IM dosing.

Prior/Concurrent Clinical Study Experience

  • Exposure to more than 4 new investigational products (including long-acting investigational products) within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product before signing of consent (OR screening) any other clinical study.
  • Participation in the study would result in loss of blood in excess of 500 mL over a 56-day period.
  • Current enrollment or past participation in this clinical study, with the exception of participants who previously completed the Oral Lead In (OLI) but for operational or logistic reasons did not progress to CRU admission and receipt of injectable suspension for injection (SFI) or powder for suspension for injection (PFS) study medication or placebo, or prior participation in study 218803.

Diagnostic Assessments

  • eGFR <60 mL/min or serum creatinine >1.1 x ULN.
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women
  • ALT or AST > upper limit of normal (ULN).
  • Total bilirubin >1.5xULN.
  • Any significant arrhythmia or ECG finding.
  • Exclusion criteria for Screening ECG - a single repeat is allowed for eligibility determination.
  • Presence of HBsAg and/or anti-HBc at Screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV antibody test.

Other Exclusions

  • Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of >14 units for males or >7 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening and at admission.
  • Sensitivity to the study drug, or components thereof, or other drug or other allergy that, in the opinion of the investigator or Sponsor Medical Monitor, contraindicates participation in the study.
  • Fasting glucose >125 mg/dL (6.95 mmol/L) or receiving treatment for elevated blood glucose.
  • Triglycerides >500 mg/dL (5.7 mmol/L) or receiving treatment for dyslipidemia.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Formulation A SC Group

Participants receive a Formulation A starting dose of VH4524184 LAI subcutaneously (SC).

VH4524184 to be taken orally.

VH4524184 LAI Formulation A administered subcutaneously.

Placebo Formulation A administered subcutaneously.

rHuPH20 administered subcutaneously.

Andre navn:
  • Halozyme ENHANZE
Eksperimentell: Formulation B SC Group

Participants receive a Formulation B starting dose of VH4524184 LAI subcutaneously (SC).

VH4524184 to be taken orally.

rHuPH20 administered subcutaneously.

Andre navn:
  • Halozyme ENHANZE

VH4524184 LAI Formulation B administered subcutaneously.

Placebo Formulation B administered subcutaneously.

Eksperimentell: Formulation A IM Group

Participants receive a Formulation A starting dose of VH4524184 LAI intramuscularly (IM).

VH4524184 to be taken orally.

VH4524184 LAI Formulation A administered intramuscularly.

Placebo Formulation A administered intramuscularly.

Eksperimentell: Formulation B IM Group

Participants receive a Formulation B starting dose of VH4524184 LAI intramuscularly (IM).

VH4524184 to be taken orally.

VH4524184 LAI Formulation B administered intramuscularly.

Placebo Formulation B administered intramuscularly.

Eksperimentell: Multiple doses Group

VH4524184 LAI formulations administered SC or IM as single doses that achieve adequate PK exposure targets, may be evaluated for safety and tolerability as multiple doses.

VH4524184 to be taken orally.

VH4524184 LAI Formulation A administered subcutaneously.

Placebo Formulation A administered subcutaneously.

rHuPH20 administered subcutaneously.

Andre navn:
  • Halozyme ENHANZE

VH4524184 LAI Formulation B administered subcutaneously.

Placebo Formulation B administered subcutaneously.

VH4524184 LAI Formulation A administered intramuscularly.

Placebo Formulation A administered intramuscularly.

VH4524184 LAI Formulation B administered intramuscularly.

Placebo Formulation B administered intramuscularly.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of participants discontinuing the treatment due to AEs
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Maximum toxicity grade increase from baseline in ALT, AST and alkaline phosphatase
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Maximum toxicity grade increase from baseline in total bilirubin
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Maximum toxicity grade increase from baseline in INR
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Duration of injection site reaction AEs
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity time (AUC[0-inf]) of LAI VH4524184 following single dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Area under the plasma drug concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-t]) of LAI VH4524184 following multiple dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Maximum observed plasma drug concentration (Cmax) of LAI VH4524184 following single dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Cmax of LAI VH4524184 following multiple dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Time to maximum observed plasma drug concentration (Tmax) of LAI VH4524184 following single dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Tmax of LAI VH4524184 following multiple dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Apparent terminal half-life (t1/2) of LAI VH4524184 following single dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
t1/2 of LAI VH4524184 following multiple dose administration
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Percentage of participants reporting adverse events (AEs) and related AEs
Tidsramme: From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Related AE = AE assessed by the investigator as related to the study drug.

From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Percentage of participants with AEs by severity
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Severity of AEs will be assessed using Division of AIDS Table for Grading the Severity of Adult Adverse Events (DAIDS). DAIDS grading scale is used to grade the toxicity associated with injection site reactions (ISR) including injection site pain (or tenderness), erythema (or redness), induration (or swelling), and pruritus. The toxicity level is graded from Grade 1 (lowest toxicity) to 4 (highest toxicity). Higher grade indicates higher toxicity.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Change from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase parameters
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

The liver panel laboratory parameters are assessed after the administration of long-acting injectable (LAI) VH4524184.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Change from baseline in total bilirubin parameters
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

The liver panel laboratory parameters are assessed after the administration of LAI VH4524184.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Change from baseline in international normalized ratio (INR) parameters
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

The liver panel laboratory parameters are assessed after the administration of LAI VH4524184.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Percentage of participants reporting injection site reaction (ISR) AEs
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life threatening.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities
Tidsramme: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Grade 3 is defined as causing an inability to perform usual social & functional activities with intervention or hospitalization indicated. Grade 4 is defined as an abnormality that is potentially life-threatening, causing an inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.

From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. mars 2024

Primær fullføring (Antatt)

28. mai 2029

Studiet fullført (Antatt)

29. juni 2029

Datoer for studieregistrering

Først innsendt

5. mars 2024

Først innsendt som oppfylte QC-kriteriene

7. mars 2024

Først lagt ut (Faktiske)

15. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Tilgangskriterier for IPD-deling

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere